Merck & Co., Inc.
http://www.merck.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Merck & Co., Inc.
Dengue Swells As US Vaccine Prospects Recede
Sanofi’s voluntary Dengvaxia withdrawal due to low demand leaves the US with no dengue vaccine, even as Puerto Rico declares a public health emergency and global cases rise.
What's Next For Phase II ADCs
BMS may have ditched an antibody-drug conjugate partnership with Eisai, but the Phase II pipeline for ADCs remains strong across the industry.
Stock Watch: New Vaccine Battlegrounds
Three new vaccines to prevent RSV infections in seniors and sales trends in pediatric vaccines highlight a shift away from childhood vaccines and a possible age-related immunity deficit.
Eisai Regains Full Control Of ADC Program After Bristol R&D Reprioritization
The Japanese pharma said it plans to accelerate development of the antibody-drug conjugate farletuzumab ecteribulin for solid tumors and will develop it independently.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abmaxis
- Acacia Biosciences
- Acceleron Pharma Inc.
- Afferent Pharmaceuticals
- ArQule, Inc.
- Avecia Biologics Limited
- Banyu Pharmaceutical Co., Ltd.
- Calporta Therapeutics
- cCAM Biotherapeutics Ltd.
- Cubist Pharmaceuticals, Inc. (Adolor Corporation (ADLR)
- Calixa Therapeutics, Inc.
- Optimer Pharmaceuticals, Inc.
- Trius Therapeutics, Inc.)
- Idenix Pharmaceuticals, Inc.
- Immune Design Corporation
- Inspire Pharmaceuticals, Inc.
- IOmet Pharma
- iOnctura SA
- Integrated Therapeutics Group
- Merck Sharp & Dohme (MSD) Pharmaceuticals Pvt. Ltd.
- MSD
- MSD K.K. (Japan)
- Nobilon International BV
- Novacardia
- OncoEthix SA
- OncoImmune, Inc.
- Organon BioSciences
- Peloton Therapeutics, Inc.
- Pandion Therapeutics, Inc.
- Rigontec GmbH
- Schering-Plough Corporation
- SmartCells, Inc.
- Tilos Therapeutics, Inc.
- Vallee S.A.
- Viralytics Limited (ASX:VLA)
- Themis Biosciences GmbH
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice